OBI Pharma, Inc. (TPEX:4174)

Taiwan · Delayed Price · Currency is TWD

34.05

-0.75 (-2.16%)

May 8, 2026, 1:30 PM CST

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
New Anticancer Drug	8.57M	3.37M	2.03M	2.00M	1.76M
New Anticancer Drug Growth	154.02%	66.16%	1.40%	14.01%	-
CDMO	69.27M	87.41M	68.83M	62.50M	34.81M
CDMO Growth	-20.75%	27.00%	10.13%	79.52%	-
Adjustments and Eliminations	-19.27M	-28.10M	-29.31M	-59.79M	-24.79M
New bispecific antibody drug	-	-	-	-	6.99M
Total	58.58M	62.68M	41.55M	4.71M	18.77M
Total Growth	-6.55%	50.85%	781.96%	-74.90%	-86.68%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Taiwan	42.16M	60.68M	39.99M	3.43M	4.13M
Taiwan Growth	-30.52%	51.74%	1065.18%	-16.92%	24.20%
Others	16.42M	2.00M	1.56M	1.28M	14.64M
Others Growth	721.31%	28.14%	21.97%	-91.26%	-89.36%
Total	58.58M	62.68M	41.55M	4.71M	18.77M
Total Growth	-6.55%	50.85%	781.96%	-74.90%	-86.68%

Source: S&P Global Market Intelligence.